Adverum Biotechnologies and Editas Medicine have entered an agreement to explore the delivery of genome editing medicines to treat inherited retinal diseases.

According to the agreement, Editas Medicine will pay an upfront fee of $1m to examine the next-generation adeno-associated viral (AAV) vectors to Adverum Biotechnologies. It will also further pay development and commercial milestone-based payments, as well as royalties on Editas products developed with Adverum Biotechnologies AAV vectors.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

BioLineRx Ltd and University of Texas MD Anderson Cancer Centre have entered an agreement to investigate BL-8040 in combination with Keytruda as a treatment for patients with metastatic pancreatic cancer.

Zydus Cadila has acquired Indian rights of Melagain lotion from Issar Pharmaceuticals Pvt. Ltd. to strengthen its dermatological portfolio.

“Zydus Cadila has acquired Indian rights of Melagain lotion from Issar Pharmaceuticals Pvt. Ltd. to strengthen its dermatological portfolio.”

The transaction enables Zydus to launch the product in other global markets and expand its presence in the key segment of the drug market.

Fibrocell Science has announced its plan to raise gross proceeds of up to $25m through the private placement of convertible promissory notes and warrants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company intends to invest the funds to advance the clinical and pre-clinical programmes of its product candidates and also for other general corporate purposes.

BioMarin Pharmaceutical Inc. has announced the underwritten public offering of its common stock shares.

Goldman, Sachs & Co. and BofA Merrill Lynch Asset Holding, Inc. are acting as joint book-running managers and Cooley LLP is acting as the legal advisor to the company.

The company expects to raise gross proceeds of $720m through the offering, and plans to use these for general corporate purposes, as well as expansion of its manufacturing capabilities.